BioCentury | Aug 14, 2000
Strategy

Monetizing gene therapy assets

With gene therapy moving more slowly than its proponents ever expected, companies are looking for ways to monetize their viral vector assets. Oxford BioMedica plc 's solution is the formation of a new gene discovery...
BioCentury | Apr 7, 1997
Finance

Active vs. passive

...to comment on whether it actually had collected the $6.5 million in proceeds. Underwriters included First United...
BioCentury | Dec 18, 1995
Analyst Picks & Changes

Analyst picks & changes

...Applied Microbiology Inc. (AMBI), Tarrytown, N.Y. Business: Food, Infectious diseases/AIDS First United Equities analyst Karl Habermas began...
Items per page:
1 - 3 of 3
BioCentury | Aug 14, 2000
Strategy

Monetizing gene therapy assets

With gene therapy moving more slowly than its proponents ever expected, companies are looking for ways to monetize their viral vector assets. Oxford BioMedica plc 's solution is the formation of a new gene discovery...
BioCentury | Apr 7, 1997
Finance

Active vs. passive

...to comment on whether it actually had collected the $6.5 million in proceeds. Underwriters included First United...
BioCentury | Dec 18, 1995
Analyst Picks & Changes

Analyst picks & changes

...Applied Microbiology Inc. (AMBI), Tarrytown, N.Y. Business: Food, Infectious diseases/AIDS First United Equities analyst Karl Habermas began...
Items per page:
1 - 3 of 3